Burns Clinical Trial
Official title:
A Randomised, Open-label Clinical Investigation of Clinical Performance and Safety of the Nanofibrillar Cellulose Wound Dressing FibDex in Paediatric and Adult Patients With Superficial Dermal Burns
This is a prospective, randomised, open-label, within-patient controlled, non-inferiority clinical investigation of the nanofibrillar cellulose (NFC) wound dressing FibDex® for treatment of superficial dermal burns in paediatric and adult patients. The clinical performance and safety of FibDex® will be compared to Epicitehydro (QRSKIN GmbH, Würzburg, Germany) and Epiprotect® (S2Medical AB, Linköping, Sweden). Epicitehydro is considered to be the primary comparator. The investigation will be conducted at 2 clinical research sites in Sweden.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | August 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year and older |
Eligibility | Inclusion Criteria: 1. Signed written informed consent (by the patient and/or the patient's parent[s]/legal guardian[s] as applicable). 2. Patient with superficial dermal burn wound(s) (class II/A) =36h as assessed by the Investigator. 3. Patient at least 1 year old. 4. Patient who has at least 3 superficial dermal burn wounds on anatomically equivalent areas or a superficial dermal burn large enough to allow a lateral comparison. 5. Wound area at least 50 cm2 (per wound, if 3 separate wounds) or at least 150 cm2 (if single wound) as judged by the Investigator. Exclusion Criteria: 1. Patient hyper-sensitive or allergic to, or have had a hypersensitivity/allergic reaction to, any of the dressing components. 2. Pregnant or breast-feeding female. 3. Patient with chemically or electrically induced burns. 4. Other non-burn wound in target wound area. 5. Not suitable for inclusion according to the Investigator. 6. Cognitive dysfunction or psychiatric history (Investigator's discretion). 7. Chronic or presently active skin condition that is judged as interfering with normal wound healing process (Investigator's discretion) 8. Target burns on sensitive skin areas, such as the facial or genital area. 9. Inability or unwillingness of participant or parent(s)/legal guardian(s) to give written informed consent. |
Country | Name | City | State |
---|---|---|---|
Sweden | Burn Centre, Uppsala University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
UPM Biomedicals | CTC Clinical Trial Consultants AB |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-inferiority of FibDex® compared to Epicitehydro in terms of time to clinical wound healing (days) defined as no need of any dressing (inner or outer) | At each clinical visit, the Investigator or delegate will assess and record in the eCRF if the inner dressing(s) has detached and judge whether or not there is a need for outer dressing. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Non-inferiority of FibDex® compared to Epiprotect® in terms of time to clinical wound healing (days) defined as no need of any dressing (inner or outer). | At each clinical visit, the Investigator or delegate will assess and record in the eCRF if the inner dressing(s) has detached and judge whether or not there is a need for outer dressing. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Non-inferiority FibDex® compared to Epicitehydro and Epiprotect®, respectively, in terms of re-epithelialisation of the initial wound area over time | Percentage of re-epithelialisation will be evaluated by visual observation by the Investigator or delegate and classified according following categories: <50%, 50-75%, 76-90%, 90-95% and 96-100%. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Evaluate degree of experienced pain | On Day 1, pain will be measured before application of FibDex® and the comparators and after outer layer dressing application. On the subsequent visits, pain will be measured before (background pain) and after (procedural pain) outer layer dressing change during the wound healing period. Patients aged =8 years will rate subjective pain using a Numeric Pain Rating Scale (NPRS) 0-10 (0 representing no pain and 10 representing the worst possible pain). Patients aged 4 to 7 years will rate pain using The Faces Pain Scale 0-10 (0 representing no pain and 10 representing very much pain). The Faces, Legs, Activity, Cry, Consolability (FLACC) 0-10 (0 is relaxed and comfortable and 7-10 is severe pain or discomfort or both) behavioural measurement will be used for assessment of pain in patients aged =3 years. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Assess clinical performance in terms of number of wound infections | The burn will be diagnosed with wound infection if at least 2 of the criteria based on the definition of burn wound infection stated by the American Burn Association, are fulfilled. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Need for surgical intervention | If wounds, during subsequent dressing changes and assessments, is judged as not progressing in a favourable direction, or if time from trauma approaches/exceeds 2 to 3 weeks, surgical intervention should be considered. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Assess clinical performance in terms of length of stay (days) at hospital | All patients hospitalised for their burns will be monitored by a research nurse. The day of discharge will be recorded in the eCRF. Any readmission after the initial discharge will also be noted in the eCRF and included in the total length of stay. | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Assess clinical performance in terms of number of outer layer dressing changes | Outer dressings will be changed at each visit (from Visit 3 and onwards) if deemed appropriate by the Investigator | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Evaluate scar quality | Burn scar outcome will be evaluated using the Patient and Observer Scar Assessment Scale (POSAS). For both the patient and the observer, the score for each item is added (1 - 10 where 10 indicates the worst imaginable sensation or scar and 1 corresponds to normal skin. Moreover, observer scale nominal variables, such as type of pigmentation, may be recorded in category boxes in addition to the 10 point scale. Lastly, the patient and observer score their "Overall Opinion" of the scar compared to normal skin with the same 10 point scale, where 1 is normal skin and 10 is the most markedly different scar. | 3, 6 and 12 months post burn | |
Secondary | Monitor Adverse Events (AEs) | Frequency, intensity and seriousness of AEs | Within 2 to 3 weeks (until the wound has healed) | |
Secondary | Monitor Device Deficiencies (DDs) | Frequency and nature of DDs | Within 2 to 3 weeks (until the wound has healed) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05023135 -
DeepView SnapShot Portable (DV-SSP): Device Training Study
|
||
Completed |
NCT05276869 -
Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
|
||
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06076031 -
Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing
|
N/A | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT03113253 -
TRANexamic Acid to Reduce Bleeding in BURN Surgery
|
Phase 4 | |
Recruiting |
NCT04090424 -
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT03159182 -
Study of Silicone Material Inserts To Treat Burn Scars
|
N/A | |
Recruiting |
NCT02904941 -
Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns
|
N/A | |
Completed |
NCT02681757 -
Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns
|
N/A | |
Recruiting |
NCT01812941 -
Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients
|
N/A | |
Completed |
NCT01437852 -
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
|
Phase 1 | |
Completed |
NCT01214811 -
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
|
Phase 3 | |
Completed |
NCT01061502 -
Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds
|
Phase 1/Phase 2 | |
Terminated |
NCT00822796 -
Thermogard™ Efficacy Trial
|
N/A | |
Terminated |
NCT00824681 -
Effect of Music Therapy on Families of Burn Patients
|
Phase 1 | |
Terminated |
NCT00634166 -
Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
|
Phase 4 | |
Terminated |
NCT00464386 -
Continuous Glucose Monitoring (POC) in the ICU
|
N/A | |
Withdrawn |
NCT00216983 -
Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding
|
N/A |